Genetic: AAV5-hRKp.RPGR

Phase 3Gene therapy

Genetic: AAV5-hRKp.RPGR is one of 2 biologic programs targeting X-Linked Retinitis Pigmentosa. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

X-Linked Retinitis PigmentosaActive, not recruiting

X-Linked Retinitis PigmentosaPhase 3

Active, not recruiting

Competition

Competitive Landscape

2 competitors in X-Linked Retinitis Pigmentosa

#DrugCompanyPhaseTrials

Genetic: AAV5-hRKp.RPGR

Johnson & Johnson

Phase 3

1 2

AAV5-Hrkp.rpgr

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 3Active, not recruiting

X-Linked Retinitis Pigmentosa

NCT04794101

Clinical

Trials by Indication[1]

Retinitis Pigmentosa1 trial

Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT04671433·105 enrolled

X-Linked Retinitis Pigmentosa1 trial

Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT04794101·97 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Genetic: AAV5-hRKp.RPGR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Genetic: AAV5-hRKp.RPGR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Genetic: AAV5-hRKp.RPGR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Genetic: AAV5-hRKp.RPGR

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Retinitis Pigmentosa1 trial

X-Linked Retinitis Pigmentosa1 trial

References

Drug Info

Quick Facts

Related News